Anecortave. Alcon Laboratories

IDrugs

Volumn 8, Issue 4, 2005, Pages 327-334

  Vinores, Stanley A ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AL 4940; ANECORTAVE; ANGIOGENESIS INHIBITOR; BENZOPORPHYRIN DERIVATIVE; CARBOPLATIN; CELECOXIB; DRUG METABOLITE; PLACEBO; PROSTAGLANDIN SYNTHASE INHIBITOR; RETAANE DEPOT; STEROID; TRIAMCINOLONE ACETATE; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; CATARACT; CLINICAL TRIAL; CONJUNCTIVAL HEMORRHAGE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG INDICATION; DRUG MECHANISM; DRUG STRUCTURE; EYE DISEASE; EYE PAIN; HUMAN; INJECTION SITE REACTION; NONHUMAN; PTOSIS; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; VISUAL IMPAIRMENT;

ANGIOGENESIS INHIBITORS; ANIMALS; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE III; DRUG INDUSTRY; DRUGS, INVESTIGATIONAL; HUMANS; PREGNADIENEDIOLS;

EID: 19744365405     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (62)

1. 271841 AL-3789: A novel ophthalmic anglostatic steroid. Clark AF EXPERT OPIN INVESTIG DRUGS 1997 6 12 1867-1877
2. 337073 Use of angiostatic steroids with photodynamic therapy to treat ocular neovascularization. Clark AF WORLD PATENT 1999 August 18 WO09903503
3. 337143 Referrals and volunteers needed for ongoing therapeutic trials. INTERNET SITE 1999 August 18 http://www.vrmny.com/
4. 337172 Efficacy and safety of topical 1% anecortave acetate (AL-3789) as anti-neovascular therapy for recurrent pterygium. Santos CI, Zeiter JH, Speaker MG, Beasley CH, DeFaller JM, Clark AF INVEST OPHTHALMOL VIS SCI 1999 40 4 S335
5. 337177 Topical formulations of novel angiostatic steroids inhibit rabbit corneal neovascularization. BenEzra D, Griffin BW, Maftzir G, Sharif NA, Clark AF INVEST OPHTHALMOL VIS SCI 1997 38 10 1954-1962
6. 347943 Anglostatic activity of steroids in the chick embryo CAM and rabbit cornea models of neovascularization. McNatt LG, Weimer L, Yanni J, Clark AF J OCUL PHARMACOL THER 1999 15 5 413-423
7. 351498 Angiogenesis: Novel Therapeutic Development - IBC International Conference. Mousa SA IDDB MEETING REPORT 1999 November 01-02
8. 443807 Alcon anecortave approval in macular degeneration expected in 2005 - IPO. FDC REPORTS PINK SHEET 2002 64 10 24
9. 443811 A clinical trial to evaluate the effect of an experimental compound on reducing the number of retreatments required in photodynamic therapy (PDT) with Visudyne™. Alcon Laboratories Inc COMPANY WORLD WIDE WEB SITE www.alconlabs.com
10. 443813 Anecortave acetate sub-Tenon's injection for age-related macular degeneration clinical program update July, 2001. Alcon Laboratories Inc COMPANY WORLD WIDE WEB SITE www.alconlabs.com
11. 450368 Alcon releases results for anecortave acetate therapy for wet age-related macullar degeneration. Alcon Inc PRESS RELEASE 2002 May 05
12. 463067 Alcon launches now anecortave acetate clinical trial for macular degeneration based on positive results from ongoing studies. Alcon Inc PRESS RELEASE 2002 September 03
13. 465399 Anecortave acetate continues to show powerful efficacy in clinical trials for age-related macular degeneration. Alcon Inc PRESS RELEASE 2002 September 28
14. 490910 Anecortave acetate as monotherapy for the treatment of subfoveal lesions in patients with exudative age-related macular degeneration (AMD): Interim (month 6) analysis of clinical safety and efficacy. D'Amico DJ, Goldberg MF, Hudson HY, Jerdan JA, Krueger S, Luna S, Robertson SM, Russell S, Singerman L, Slakter JS, Sullivan EH et al RETINA 2003 23 1 14-23
15. 490912 The effect of an angiostatic steroid on neovascularization in a rat model of retinopathy of prematurity. Penn JS, Rajaratnam VS, Collier RJ, Clark AF INVEST OPHTHALMOL VIS SCI 2001 42 1 283-290
16. 490915 Inhibition of intraocular tumor growth by topical application of the angiostatic steroid anecortave acetate. Clark AF, Mellon J, Li XY, Ma D, Leher H, Apte R, Alizadeh H, Hedge S, Mayhew E, D'Orazio TJ, Niederkom JY INVEST OPHTHALMOL VIS SCI 1999 40 9 2158-2162
17. 501387 Anecortave acetate demonstrates significant long-term efficacy in wet age-related macular degeneration patients. Alcon Inc PRESS RELEASE 2003 August 18
18. 510076 Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: One-year results of 2 randomized clinical trials - TAP report. No authors listed ARCH OPHTHALMOL 1999 117 10 1329-1345
19. 513152 Alcon to initiate new anecortave acetate clinical trials for age-related macular degeneration. Alcon Inc PRESS RELEASE 2003 November 13
20. 533974 Alcon's first quarter earnings rise 46.7 percent on 19.4 percent sales growth. Alcon Inc PRESS RELEASE 2004 April 20
21. 535342 Anecortave acetate as monotherapy for treatment of subfoveal neovascularization in age-related macular degeneration: Twelve-month clinical outcomes. D'Amico DJ, Goldberg MF, Hudson H, Jerdan JA, Krueger DS, Luna SP, Robertson SM, Russell S, Singerman L, Slakter JS, Yannuzzi L et al OPHTHALMOLOGY 2003 110 12 2372-2383
22. 539804 Alcon presents RETAANE 15 mg depot clinical update at Association for Research and Vision in Ophthalmology Annual Meeting. Alcon Inc PRESS RELEASE 2004 May 20
23. 541810 Alcon Inc presented Retaane 15mg depot clinical update at 4th EURETINA Congress. Alcon Inc PRESS RELEASE 2004 June 02
24. 547113 Alcon updates filing status of RETAANE now drug application. Alcon Inc PRESS RELEASE 2004 June 02
25. 564434 Alcon announces anecortave acetate clinical results. Alcon Inc PRESS RELEASE 2004 June 30
26. 566165 Alcon presents more Retaane® clinical information to retinal specialists. Alcon Inc PRESS RELEASE 2004 October 21
27. 573429 Limited macular translocation for the management of subfoveal choroidal neovascularization after photodynamic therapy. Fujii GY, de Juan E Jr, Humayun MS, Chang TS AM J OPHTHALMOL 2003 135 1 109-112
28. 573946 Age-related macular degeneration: Epidemiology and optimal treatment. la Cour M, Kiilgaard JF, Nissen MH DRUGS AGING 2002 19 2 101-133
29. 573955 Prevalence of senile cataract, diabetic retinopathy, senile macular degeneration, and open-angle glaucoma in the Framingham eye study. Kini MM, Leibowitz HM, Colton T, Nickerson RJ, Ganley J, Dawber TR AM J OPHTHALMOL 1978 85 1 28-34
30. 573981 The eye in old age. V. Diseases of the macula: A clinicopathologic study. Kornzweig AL AM J OPHTHALMOL 1965 60 5 835-843
31. 573994 Risk factors for age-related macular degeneration: Pooled findings from three continents. Smith W, Assink J, Klein R, Mitchell P, Klaver CC, Klein BE, Hofman A, Jensen S, Wang JJ, de Jong PT OPHTHALMOLOGY 2001 108 4 697-704
32. 574006 Age-related macular degeneration. Fine SL, Berger JW, Maguire MG, Ho AC N ENGL J MED 2000 342 7 483-492
33. 574008 An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration. Hageman GS, Luthert PJ, Victor Chong NH, Johnson LV, Anderson DH, Mullins RF PROG RETINAL EYE RES 2001 20 6 705-732
34. 574010 Changes in choriocapillaris and retinal pigment epithelium in age-related macular degeneration. Lutty G, Grunwald J, Majji AB, Uyama M, Yoneya S INVEST OPHTHALMOL VIS SCI 1999 3 5 35
35. 574047 Genetic factors of age-related macular degeneration. Tuo J, Bojanowskii CM, Chan CC PROG RETINAL EYE RES 2004 23 2 229-249
36. 574049 Age-related macular degeneration: Etiology, pathogenesis, and therapeutic strategies. Ambati J, Ambati BK, Yoo SH, Ianchulev S, Adamis AP SURV OPHTHALMOL 2003 48 3 257-293
37. 574051 "Oxidative protector" enzymes in the macular retinal pigment epithelium of aging eyes and eyes with age-related macular degeneration. Frank RN TRANS AM OPHTHALMOL SOC 1998 96 635-689
38. 574052 Antioxidant enzymes in the macular retinal pigment epithelium of eyes with neovascular age-related macular degeneration. Frank RN, Amin RH, Puklin JE AM J OPHTHALMOL 1999 127 6 694-709
39. 574054 A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, β carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. ARCH OPHTHALMOL 2001 119 10 1417-1436
40. 574055 Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. ARCH OPHTHALMOL 1991 109 1220-1231
41. 574058 Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-Year results of a randomized clinical trial - VIP report no. 1. OPHTHALMOLOGY 2001 108 5 841-852
42. 574059 Antiangiogenesis agents. Ciardella AP, Donsoff IM, Guyer DR, Adamis A, Yannuzzi LA OPHTHALMOLOGY CLINICS NORTH AMERICA 2002 15 4 453-458
43. 574060 Photodynamic therapy for choroidal neovascular disease: Photosensitizers and clinical trials. Lim JI OPHTHALMOLOGY CLINICS NORTH AMERICA 2002 15 4 473-478
44. 574062 Who should receive oral supplement treatment for age-related macular degeneration? McBee WL, Lindblad AS, Ferris FL 3rd CURR OPIN OPHTHALMOL 2003 14 3 159-162
45. 574064 An update on photodynamic therapy in age-related macular degeneration. Rechtman E, Ciulla TA, Criswell MH, Pollack A, Harris A EXPERT OPIN PHARMACOTHER 2002 3 7 931-938
46. 574071 Local delivery of anecortave acetate inhibits laser-induced choroidal neovascularization (CNV) in the mouse. Bingaman DP, Liu C, Landers RA, Gu X ANN MEET ASSOC RES VISION OPTHTALMOL 2004 Abs 1850
47. 574073 Inhibition of VEGF-induced endothelial cell proliferation and differentiation by steroidal and non-steroidal COX Inhibitors with variable COX-1/COX-2 selectivity. Yang R, McCollum GW, Bingaman DP, Penn JS ANN MEET ASSOC RES VISION OPTHTALMOL 2004 Abs 1914
48. 574075 Subconjunctival anecortave acetate, an angiostatic steroid in the treatment of a murine model of retinoblastoms. Murray TG, Escalona-Benz E, Hayden BC, Cicciarelli N, Hernandez E, Windle JJ ANN MEET ASSOC RES VISION OPTHTALMOL 2003 Abs 934
49. AG murine transgenic model of retinoblastoma. Murray TG, Alcon F ANN MEET ASSOC RES VISION OPTHTALMOL 2004 45 Abs 3362
50. 574078 An evaluation of an episcleral anecortave acetate transscleral drug delivery system in rhesus monkey. Olsen TW, Yaacobi Y, Parks M, Flowers R, Fang X, Hubbard W, Pilon K ANN MEET ASSOC RES VISION OPTHTALMOL 2003 Abs 4213
51. 574081 In-vivo studies with trans-scleral anecortave acetate delivery device designed to treat choroidal neovascularization in AMD. Yaacobi Y, Chastain J, Lowseth L, Bhatia R, Slovin E, Rodstrom R, Stevens L, Dahlin D, Marsh D ANN MEET ASSOC RES VISION OPTHTALMOL 2003 Abs 4210
52. 574085 Design of a specialized cannula for posterior juxtascleral delivery of anecortave acetate to the retina for treatment CNV associated with age-related macular degeneration (AMD). Dahlin DC, Trawick D, Zilliox P, Robertson SM, Sanders M, Struble C, Clark AF ANN MEET ASSOC RES VISION OPTHTALMOL 2003 Abs 5036
53. 574087 Anecortave acetate administered subTenon's retrobulbar with and without Visudyne PDT in patients with subfoveal age-related macular degeneration (AMD) - clinical safety profile. D'Amico DJ, Duker J, Regillo C, Schneebaum C, Beasley C ANN MEET ASSOC RES VISION OPTHTALMOL 2002 Abs 569
54. 574088 Anecortave acetate monotherapy for the treatment of occult and minimally classic choroidal neovascularization in age-related macular degeneration. Kitchens JW, Lotery A, Russell SR ANN MEET ASSOC RES VISION OPTHTALMOL 2003 Abs 5039
55. 574089 Evaluation of the safety and efficacy of anecortave acetate 15 mg for depot suspension and triamcinolone acetate 4 mg or a combination of both in patients with exudative age-related macular degeneration (AMD). Slakter JS, Sorenson JA, Spaide RF, Freund KB ANN MEET ASSOC RES VISION OPTHTALMOL 2004 Abs 1927
56. 574090 Anecortave acetate in the treatment of age-related macular degeneration (AMD). Slakter JS ANN MEET ASSOC RES VISION OPTHTALMOL 2004 Abs 1110
57. 574091 Anecortave acetate treatment of "dry" AMD to reduce risk of progression to "wet" AMD - the anecortave acetate risk reduction trial (AART). Russell SR, Slakter JS, Ho AC, Kaiser PK, Regillo CD, Schmidt-Erfurth UM, Coscas GJ, Simpson G, Jerdan JA ANN MEET ASSOC RES VISION OPTHTALMOL 2004 Abs 3134
58. 574111 Plasma pharmacokinetics of AL-4940, the active metabolite of anecortave acetate, following posterior juxtascleral injections in patients with age-related macular degeneration. Hudson HL, Faulkner RD, Patil SD, Schaffer H, Curtis M, Dahlin DC INVEST OPHTHALMOL VIS SCI 2003 44 Abs 5000
59. 576597 Alcon submits Retaane® drug applications to U.S. and European Regulatory Authorities. Alcon Inc PRESS RELEASE December 16
60. 583976 Association for Ocular Pharmacology and Therapeutics - Seventh Meeting, Catania, Italy. Toris C IDDB MEETING REPORT 2005
61. 587208 Now RETAANE clinical study date reported at Macula Society Meeting. Alcon Laboratories Inc PRESS RELEASE 2005 February 25
62. 589334 Alcon updates filing status of Retaane new drug application. Alcon Laboratories Inc PRESS RELEASE 2004 June 30